Similarly, TG2-induced NF-κB activation was implicated in resistance to cisplatin in ovarian cancer cells, and the synergistic interaction between TG2 inhibitor KCC009 and cisplatin suggests that the transamidation activity of TG2 is essential for NF-κB activation [41], [42]. The gene discussed is TGM2; the disease is ovarian cancer.